Zhitong Finance App News, Cinda Biotech (01801.HK) announced that in the third quarter of 2026, the company's business continued to grow strongly. Product revenue exceeded RMB 4.7 billion, an increase of more than 40% over the previous year, fully confirming the strong momentum and continuous implementation of the two-wheel drive strategy. The market penetration of major new products in the integrated pipeline, Xinermei® (Maxilizumab injection), and Cybimin® (tetuyumab N01 injection) continues to increase; various tyrosine kinase inhibitor (TKI) products in the tumor product line have achieved rapid sales growth, which jointly promotes the overall growth of the company's commercial product portfolio. The diverse product matrix collaborates to drive continuous optimization of the revenue structure and richer growth engines.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.